Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00819468 · ClinicalTrials.gov registry record · Phase 1

Pharmacokinetics (PK) of 20 mg Teduglutide in Participants With Moderately Impaired Hepatic Function Compared to Healthy Participants

A Phase 1 study, sponsored by Shire.

Completed
Registry status
Phase 1
Development phase
24
Enrollment target

NCT00819468 is a Phase 1 study that has completed, run by Shire. The registered enrollment target is 24 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00819468, a Phase 1 study, has completed, sponsored by Shire.

COMPLETED
Registry status
Phase 1
Development phase
24 participants
Enrollment target

Study Summary

This is a study to compare the pharmacokinetic profile of teduglutide in healthy participants with normal hepatic function with participants who have moderate hepatic impairment.

Interventions

  • DRUG Teduglutide

Trial Details

FieldValue
Enrollment Target 24 participants
Start Date 2007-07-26
Est. Completion 2007-08-23
Phase Phase 1

Sponsor

Shire

245 total trials

What the Registry Record Tells You About NCT00819468

The ClinicalTrials.gov registry entry for NCT00819468 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Shire, which has 245 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which Teduglutide is the first listed.

NCT00819468 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00819468 about?

NCT00819468 is a clinical study titled "Pharmacokinetics (PK) of 20 mg Teduglutide in Participants With Moderately Impaired Hepatic Function Compared to Healthy Participants". This is a study to compare the pharmacokinetic profile of teduglutide in healthy participants with normal hepatic function with participants who have moderate hepatic impairment.

What is the current status of trial NCT00819468?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2007-07-26. Estimated completion is 2007-08-23.

What interventions are being tested in trial NCT00819468?

The interventions under investigation include: Teduglutide (DRUG).

Who is sponsoring clinical trial NCT00819468?

This trial is sponsored by Shire, which has 245 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.